Application of CRISPR/Cas9 Technology to HBV
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/11/25950 |
id |
doaj-02d7845d4e924b1dbf4865fd0ecdafdd |
---|---|
record_format |
Article |
spelling |
doaj-02d7845d4e924b1dbf4865fd0ecdafdd2020-11-25T01:30:47ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-11-011611260772608610.3390/ijms161125950ijms161125950Application of CRISPR/Cas9 Technology to HBVGuigao Lin0Kuo Zhang1Jinming Li2National Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, ChinaNational Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, ChinaNational Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, ChinaMore than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV.http://www.mdpi.com/1422-0067/16/11/25950CRISPR/Cas9HBVcccDNAantiviral |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guigao Lin Kuo Zhang Jinming Li |
spellingShingle |
Guigao Lin Kuo Zhang Jinming Li Application of CRISPR/Cas9 Technology to HBV International Journal of Molecular Sciences CRISPR/Cas9 HBV cccDNA antiviral |
author_facet |
Guigao Lin Kuo Zhang Jinming Li |
author_sort |
Guigao Lin |
title |
Application of CRISPR/Cas9 Technology to HBV |
title_short |
Application of CRISPR/Cas9 Technology to HBV |
title_full |
Application of CRISPR/Cas9 Technology to HBV |
title_fullStr |
Application of CRISPR/Cas9 Technology to HBV |
title_full_unstemmed |
Application of CRISPR/Cas9 Technology to HBV |
title_sort |
application of crispr/cas9 technology to hbv |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2015-11-01 |
description |
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV. |
topic |
CRISPR/Cas9 HBV cccDNA antiviral |
url |
http://www.mdpi.com/1422-0067/16/11/25950 |
work_keys_str_mv |
AT guigaolin applicationofcrisprcas9technologytohbv AT kuozhang applicationofcrisprcas9technologytohbv AT jinmingli applicationofcrisprcas9technologytohbv |
_version_ |
1725089927895449600 |